Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera

Mostrar otras versiones (1)

Rapidly spreading variants of SARS-CoV-2 that have arisen in the United Kingdom and South Africa share the spike N501Y substitution, which is of particular concern because it is located in the viral receptor binding site for cell entry and increases binding to the receptor (angiotensin converting en...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Xuping, Zou, Jing, Fontes-Garfias, Camila R., Xia, Hongjie, Swanson, Kena A., Cutler, Mark, Cooper, David, Menachery, Vineet D., Weaver, Scott, Dormitzer, Philip R., Shi, Pei-Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7805448/
https://www.ncbi.nlm.nih.gov/pubmed/33442691
http://dx.doi.org/10.1101/2021.01.07.425740
_version_ 1783636312906006528
author Xie, Xuping
Zou, Jing
Fontes-Garfias, Camila R.
Xia, Hongjie
Swanson, Kena A.
Cutler, Mark
Cooper, David
Menachery, Vineet D.
Weaver, Scott
Dormitzer, Philip R.
Shi, Pei-Yong
author_facet Xie, Xuping
Zou, Jing
Fontes-Garfias, Camila R.
Xia, Hongjie
Swanson, Kena A.
Cutler, Mark
Cooper, David
Menachery, Vineet D.
Weaver, Scott
Dormitzer, Philip R.
Shi, Pei-Yong
author_sort Xie, Xuping
collection PubMed
description Rapidly spreading variants of SARS-CoV-2 that have arisen in the United Kingdom and South Africa share the spike N501Y substitution, which is of particular concern because it is located in the viral receptor binding site for cell entry and increases binding to the receptor (angiotensin converting enzyme 2). We generated isogenic N501 and Y501 SARS-CoV-2. Sera of 20 participants in a previously reported trial of the mRNA-based COVID-19 vaccine BNT162b2 had equivalent neutralizing titers to the N501 and Y501 viruses.
format Online
Article
Text
id pubmed-7805448
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cold Spring Harbor Laboratory
record_format MEDLINE/PubMed
spelling pubmed-78054482021-01-14 Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera Xie, Xuping Zou, Jing Fontes-Garfias, Camila R. Xia, Hongjie Swanson, Kena A. Cutler, Mark Cooper, David Menachery, Vineet D. Weaver, Scott Dormitzer, Philip R. Shi, Pei-Yong bioRxiv Article Rapidly spreading variants of SARS-CoV-2 that have arisen in the United Kingdom and South Africa share the spike N501Y substitution, which is of particular concern because it is located in the viral receptor binding site for cell entry and increases binding to the receptor (angiotensin converting enzyme 2). We generated isogenic N501 and Y501 SARS-CoV-2. Sera of 20 participants in a previously reported trial of the mRNA-based COVID-19 vaccine BNT162b2 had equivalent neutralizing titers to the N501 and Y501 viruses. Cold Spring Harbor Laboratory 2021-01-07 /pmc/articles/PMC7805448/ /pubmed/33442691 http://dx.doi.org/10.1101/2021.01.07.425740 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which allows reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator.
spellingShingle Article
Xie, Xuping
Zou, Jing
Fontes-Garfias, Camila R.
Xia, Hongjie
Swanson, Kena A.
Cutler, Mark
Cooper, David
Menachery, Vineet D.
Weaver, Scott
Dormitzer, Philip R.
Shi, Pei-Yong
Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera
title Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera
title_full Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera
title_fullStr Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera
title_full_unstemmed Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera
title_short Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera
title_sort neutralization of n501y mutant sars-cov-2 by bnt162b2 vaccine-elicited sera
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7805448/
https://www.ncbi.nlm.nih.gov/pubmed/33442691
http://dx.doi.org/10.1101/2021.01.07.425740
work_keys_str_mv AT xiexuping neutralizationofn501ymutantsarscov2bybnt162b2vaccineelicitedsera
AT zoujing neutralizationofn501ymutantsarscov2bybnt162b2vaccineelicitedsera
AT fontesgarfiascamilar neutralizationofn501ymutantsarscov2bybnt162b2vaccineelicitedsera
AT xiahongjie neutralizationofn501ymutantsarscov2bybnt162b2vaccineelicitedsera
AT swansonkenaa neutralizationofn501ymutantsarscov2bybnt162b2vaccineelicitedsera
AT cutlermark neutralizationofn501ymutantsarscov2bybnt162b2vaccineelicitedsera
AT cooperdavid neutralizationofn501ymutantsarscov2bybnt162b2vaccineelicitedsera
AT menacheryvineetd neutralizationofn501ymutantsarscov2bybnt162b2vaccineelicitedsera
AT weaverscott neutralizationofn501ymutantsarscov2bybnt162b2vaccineelicitedsera
AT dormitzerphilipr neutralizationofn501ymutantsarscov2bybnt162b2vaccineelicitedsera
AT shipeiyong neutralizationofn501ymutantsarscov2bybnt162b2vaccineelicitedsera

Ejemplares similares